ACTU
Actuate Therapeutics, Inc. Common stockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$56.94M
P/E Ratio
—
EPS
$-0.98
Beta
—
52W High
$11.99
52W Low
$1.58
50-Day MA
$2.54
200-Day MA
$5.40
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for serious diseases, with a particular emphasis on oncology. The company is advancing its proprietary drug candidates through rigorous clinical trials to tackle significant unmet medical needs and improve patient outcomes. By cultivating a robust pipeline focused on transformative therapeutic solutions, Actuate aims to drive strategic growth and deliver substantial value to its investors, reinforcing its competitive stance within the biotechnology sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -554.00% |
| Return on Assets | -203.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.16 |
| Price-to-Book | 15.05 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $23.93M |
| Float | $8.57M |
| % Insiders | 15.36% |
| % Institutions | 58.16% |
Historical Volatility
HV 10-Day
78.44%
HV 20-Day
79.84%
HV 30-Day
127.78%
HV 60-Day
128.75%
HV Rank
90.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($9.98 target)
4
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026